Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H14N4O3S |
| Molecular Weight | 294.33 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1C=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC1=O
InChI
InChIKey=SIBQAECNSSQUOD-UHFFFAOYSA-N
InChI=1S/C12H14N4O3S/c1-2-16-8-7-11(14-12(16)17)15-20(18,19)10-5-3-9(13)4-6-10/h3-8H,2,13H2,1H3,(H,14,15,17)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/769287
Sources: https://www.ncbi.nlm.nih.gov/pubmed/769287
Sulfacytine is a short-acting sulfonamide, which was used for the treatment uncomplicated urinary tract infections, but was discontinued. This drug is a is a competitive inhibitor of the dihydropteroate synthetase, that inhibits bacterial synthesis of dihydrofolic acid by preventing the condensation of the peridine with para-aminobenzoic acid (PABA), a substrate of the enzyme dihydropteroate synthetase.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2013 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1195474 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | RENOQUID Approved UseUnknown Launch Date1975 |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3606051/ |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
SULFACYTINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3606051/ |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
SULFACYTINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Sulfacytine vs. sulfisoxazole for urinary tract infections in an obstetric-gynecologic population. | 1976-06 |
|
| Sulfacytine in uncomplicated urinary tract infections. Double-blind comparison with sulfisoxazole. | 1976-03 |
|
| Double-blind comparison of sulfacytine, a new sulfonamide, with sulfisoxazole in acute uncomplicated urinary tract infections. | 1976-02 |
|
| Sulfacytine: a new sulfonamide. Double-blind comparison with sulfisoxazole in acute uncomplicated urinary tract infections. | 1975-12 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/769287
1Gm per day
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29739
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2891
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY | |||
|
78902
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000083262
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY | |||
|
DTXSID6023606
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201056
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY | |||
|
Sulfacytine
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY | |||
|
C47734
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY | |||
|
T795873AJP
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY | |||
|
5322
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY | |||
|
1401-49-6
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
NO STRUCTURE GIVEN | |||
|
2499
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY | |||
|
m10304
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY | Merck Index | ||
|
356717
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY | |||
|
3272
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY | |||
|
SUB10690MIG
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY | |||
|
17784-12-2
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY | |||
|
C100141
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY | |||
|
DB01298
Created by
admin on Wed Apr 02 09:30:25 GMT 2025 , Edited by admin on Wed Apr 02 09:30:25 GMT 2025
|
PRIMARY |
ACTIVE MOIETY